Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

 Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Shots:

  • Cue Biopharma will conduct a P-I KEYNOTE-A78 study assessing the combination therapy as 1L treatment for HPV+ advanced head and neck cancer. KEYNOTE-A78 will be conducted in parallel with the ongoing P-I study assessing CUE-101 as monothx. post 1L treatment
  • The ongoing P-I dose-escalation and expansion study assessing CUE-101 as a monothx. in post 1L recurrent/m-HNSCC patients to be amended to include combination therapy as 1L treatment
  • The data from early patient cohorts in P-I monothx. study demonstrated tolerability and drug exposure and provides drug activity consistent with projections based on preclinical data. The company is expecting the initial PD data from P-I monothx. part of the study in H1’20

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image:  NJTV

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post